ASCO GU 2024

Cabo + IO: Interesting but not practice changing?!

Is "more" always better?

Combination vs. monotherapy - a great new option for…

Gleason 3+3 - cancer or not?

Higher radiation is effective in high-risk PCA

Enzalutamide therapy as option for biochemical…

BRCAaway - PARP combination study

Stockholm3 validated in multiethnic cohort

Localized PCa - news for radiotherapy and biochemical…

Further testing before olaparib combination

Dose de-escalation in different ways

Relugolix combined with androgen signaling in real word…

Quality of life under intensive therapy

Still a difficult time for androgenic inhibitors in…

First positive study of IO therapy in mCRPC

Cognitive function in ART treatment

Combination of cabozantinib & checkpoint inhibitor

Evaluating the recombination-repair mutations in…

Olaparib + Arbiraterone better compared to either alone

Salvage radiation with anti-androgen superior to…

Insights and news for mCRPC

Combination NHT + PARP makes sense

What about the clinical benefit?

Therapy Intensification Still Neglected in mHSPC

SEPTA calismasi: Stockholm3 un multietnik hasta…

Κορυφαίες Στιγμές για τον Καρκίνο του Προστάτη στο ASCO…

Une période encore difficile pour les inhibiteurs…

Kognitiv påverkan av abirateron och enzalutamid?

BRCAAway - PARP hämmare, abiraterone eller i…

mCRPC de Olaparib+Abi , tek tek herbirinden ustun

Gleason 3+3 ska vi kalla de cancer eller inte?

PCa Tedavisinde Deeskalasyon (Tedavi Azaltimi) Orta…

Kombination av cabozantinib och immunterapi

Advances in (neo)-adjuvant treatment in urothelial…

New standard of care, but still open questions!

The emerging field of biomarkers in bladder cancer

Pembrolizumab adjuvant in bladder cancer

Highlights in bladder cancer at ASCO GU24

Another success for an ICI?

MIBC: adjuvant PD1 - all set?!

Update on EV-302

EV + Pembro new first-line standard in localized…

Adjuvant Nivolumab Shows Promise in Boosting Long-Term…

Should we start forgetting the Galsky Criteria in…

Biomarker update

Adjuvant therapy in urothelial carcinoma : is the…

Update M1 urothelial cancer

HER2 and bladder cancer

Perioperative adjuvant therapy in urothelial cancer

EV as standard in 3rd line mUC

Encore un succès pour une ICI ?

Tratamiento adyuvante en cancer urotelial: ¿está…

Terapia adyuvante perioperatoria en el cáncer de vejiga

νέα δεδομένα για το ουροθηλιακο καρκίνωμα από ASCO GU24

Novedades sobre EV-302

Adjuvant therapy in kidney cancer: Is immunotherapy the…

Subcutaneous vs. intravenous application: ready for…

Trial updates at ASCO GU24: Are the follow-up data…

Perioperative treatment in renal cell carcinoma - did…

Practice changing adjuvant therapy?!

Durable effects of Ipi-Nivo

Belzutifan: Updates on QoL

Tumorburden and outcome

Subcutaneous Nivolumab Matches IV Formulation in Clear…

ASCO GU24 - Highlights in renal cell carcinoma

Long-term follow-up of first-line trials

Overall survival benefit - Pembro after surgery

Nivolumab/Cabozantinib Outshines Sunitinib in Landmark…

Long-term outcome

Better QoL with Belzutifan

Highlights in kidney cancer at ASCO GU24

Cabozantinib Plus Atezolizumab in Adrenocortical…

Tratamiento perioperatorio en cancer renal: ¿Hemos…